Shijie Wang

Shijie Wang

Auto-generated profile, based on publicly available information

Shijie Wang

Department of Radiation Oncology, China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Hepatology
Verified
Journal Article
Closed access
PDF file
JHJianglong Han
Jianglong Han
BWBin Wang
Bin Wang
WLWenmin Liu
Wenmin Liu
SWShijie Wang
Shijie Wang
RCRuyan Chen
Ruyan Chen
ZFZhenming Fu
Zhenming Fu

26 October 2023 in Translational Oncology
Verified
Journal Article
Open access
YYYuncang Yuan
Yuncang Yuan
JFJiawei Fan
Jiawei Fan
DLDandan Liang
Dandan Liang
SWShijie Wang
Shijie Wang
XLXu Luo
Xu Luo
ZXZhao Xudong
Zhao Xudong
Pancreatic cancer is a highly lethal solid malignancy with limited treatment options. Chimeric antigen receptor T (CAR-T) cell therapy has been successfully applied to treat hematological malignancies, but faces many challenges in solid tumors. One major challenge is the shortage of tumor-selective targets. Cell surface GRP78 (csGRP78) is highly expressed on various solid cancer cells including pancreatic cancer, but not normal cells, providing a potential target for CAR-T cell therapy in pancreatic cancer. Here, we demonstrated that csGRP78-directed CAR-T (GRP78-CAR-T) cells effectively killed the human pancreatic cancer cell lines Bxpc-3-luc, Aspc-1-luc and MIA PaCa-2-luc, and pancreatic cancer stem-like cells derived from Aspc-1-luc cells and MIA PaCa-2-luc cells in vitro by a luciferase-based cytotoxicity assay. Importantly, we showed that GRP78-CAR-T cells efficiently homed to and infiltrated Aspc-1-luc cell-derived xenografts and significantly inhibited pancreatic tumor growth in vivo by performing mouse xenograft experiments. Interestingly, we found that gemcitabine treatment increased csGRP78 expression in gemcitabine-resistant MIA PaCa-2-luc cells, and the coapplication of gemcitabine with GRP78-CAR-T cells led to a robust cytotoxic effect on these cells in vitro. Taken together, our study demonstrates that csGRP78-directed CAR-T cells, alone or in combination with chemotherapy, selectively and efficiently target csGRP78-expressing pancreatic cancer cells to suppress pancreatic tumor growth.

22 January 2009 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
GWGui‐Ying Wang
Gui‐Ying Wang
Yong LiYong Li
Yong Li
YYYueming Yu
Yueming Yu
BYBin Yu
Bin Yu
ZZZhen‐Ya Zhang
Zhen‐Ya Zhang
SWShi‐Jie Wang
Shi‐Jie Wang

15 January 2026 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
SWShijie Wang
Shijie Wang
CXChangdan Xu
Changdan Xu
XXXiaohong Xu
Xiaohong Xu
WSWeipeng Shao
Weipeng Shao
GWGuohui Wang
Guohui Wang
GZGuangying Zhu
Guangying Zhu
Purpose Our previous study showed that circulating tumor cell (CTC) count combined with gene mutation detection might help differentiate benign and malignant pulmonary nodules (PNs). Herein, we aimed to expand the study cohort and conduct further sequencing analysis.Materials and Methods Patients with PNs were included, and CTCs were identified before operation. Low-coverage whole-genome sequencing (LC-WGS) and lung cancer-related targeted gene sequencing were performed on CTCs. The diagnostic efficacy was evaluated by receiver operating characteristic (ROC) curve. The differences in CTC counts among subgroups classified by demographic–clinical characteristics were analyzed. LC-WGS–based copy number variation (CNV) analysis and targeted gene mutation analysis were conducted.Results A total of 172 patients were included. CTC count of 2.5 was identified by the ROC curves as the optimal diagnostic cutoff. The sensitivity and specificity of CTC count for differentiating benign and malignant PNs were 54.2% and 78.6%, respectively. The diagnostic sensitivity and specificity of combined CTC count, radiological nodule type, and any malignant imaging features were 84.7% and 71.4%, respectively. The CTC counts were significantly greater in patients with aggressive tumors, later stage, and spread through air spaces. CTCs from malignant cases had more CNVs than those from benign cases.Conclusion CTC count can be used in identifying malignant PNs. The diagnostic efficacy can be improved if combined with computed tomography imaging characteristics. Further CNV analysis might help differential diagnosis. Greater CTC count might suggest more aggressive tumors. CTC detection can provide important information and guidance for subsequent management of PNs.

23 August 2020 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
SWShijie Wang
Shijie Wang
MJMingfang Jia
Mingfang Jia
JHJianglong Han
Jianglong Han
RZRui Zhang
Rui Zhang
KHKejie Huang
Kejie Huang
ZFZhenming Fu
Zhenming Fu
The survival advantage of radiotherapy for patients with stage IV classic Hodgkin lymphoma (HL) has not been adequately evaluated. We analyzed patients with stage IV HL enrolled from the Surveillan...